The application relates a migraine patch (NP101 or Zelrix) which delivers sumatriptan using an iontophoretic technique to achieve consistent therapeutic plasma levels with low patient-to-patient variability to treat migraine.

The patch uses the comapny’s proprietary transdermal delivery technology, SmartRelief, that allows the rapid yet tightly controlled transport of medication through the skin.

NuPathe said once the patent is issued, it will provide additional patent protection through April 2027 for its migraine patch.

NuPathe CEO Jane Hollingsworth said issuance of this patent will further strengthen their intellectual property related to NP101.

"We look forward to re-submitting our NDA for the migraine patch in the first half of this year," Hollingsworth said.